Also, the expression level of LOX-1 was obviously increased in advanced-stage cancer (TNM III) compared with early-stage cancer (TNM II) (Fig. 2a), and the expressional difference of LOX-1 in TNM III/IV stage and TNM I/II stage was statistically significant (7.965 ± 2.138 vs 6.744 ± 2.381; P = 0.008; Fig. 2b), which was further confirmed by GSE15459 database (3.819 ± 6.059 vs 1.378 ± 1.179; P = 0.002; Fig. 2c). This evidence concerns the gene OLR1 and cancer.